A Study of Furmonertinib Combined With Chemotherapy in the Treatment of NSCLC With Leptomeningeal Metastasis
Trial Parameters
Brief Summary
Leptomeningeal metastasis is a fatal complication of advanced lung cancer. There is no standard treatment for leptomeningeal metastasis after third-generation EGFR-TKIs. The Furmonertinib prototype persists longer in brain tissue, and its metabolites can also penetrate the blood-brain barrier. Ommaya cystlateral ventricle chemotherapy can quickly control the progression of intracranial lesions. The aim of this study is to evaluate the LM progression-free survival (LM-PFS) of Furmonertinib combined with lateral ventricular chemotherapy in the treatment of leptomeningeal metastatic NSCLC after third-generation EGFR-TKIs resistance.
Eligibility Criteria
Inclusion Criteria: * aged 18-75 years old (including 18 and 75 years old); * ECOG PS 0-3 with no deterioration in the first 2 weeks； * The lowest expected survival time was ≥12 weeks； * NSCLC patients with EGFR sensitive mutations confirmed by tissue and/or cytology; * Patients with EGFR sensitive mutations (EGFR exon 19 deletion or EGFR exon 21 L858R mutation) without other driver genes with targeted therapy (such as C797X mutation, MET abnormality, etc.) were enrolled； * Leptomeningeal metastasis after resistance to third-generation EGFR-TKIs; * Histologically confirmed NSCLC LM patients by positive CSF cytology. The diagnosis of LM can be based on MRI with malignant cells in the cerebrospinal fluid, focal or diffuse enhancement of the leptomeninges, and enhancement of nerve roots or ependymal surfaces; * no severe liver and kidney dysfunction; * no other serious chronic diseases; * Women should use adequate contraceptive methods throughout the study; Termination of pregnancy was re